Skip to Content

Promacta Approval History

Promacta (eltrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

Development History and FDA Approval Process for Promacta

Aug 24, 2015Approval FDA Extends Use of Promacta (eltrombopag) in Pediatric Patients with Immune Thrombocytopenic Purpura
Jun 12, 2015Approval FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Aug 26, 2014Approval FDA Approves New Indication for Promacta (eltrombopag) for Severe Aplastic Anemia
Nov 19, 2012Approval FDA Approves New Indication for Promacta (eltrombopag)
Nov 21, 2008Approval FDA Approves Promacta (eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
Jun 23, 2008Ligand Partner GlaxoSmithKline Receives FDA Extended Priority Review for Promacta NDA
May 30, 2008Promacta (eltrombopag) Receives Unanimous Recommendation by FDA Advisory Panel
Mar  3, 2008FDA Grants Priority Review for Promacta (eltrombopag)
Dec 21, 2007Ligand Earns $1 Million Milestone Payment as GlaxoSmithKline Submits New Drug Application for Promacta (eltrombopag)
Dec 20, 2007GlaxoSmithKline Files for FDA Approval of Promacta (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.